Abbott
Abbott Laboratories (ABT) is a diversified global healthcare company operating across diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. With a market capitalisation around $221.98B, Abbott supplies a mix of recurring-revenue products — from diagnostic systems and cardiovascular devices to glucose-monitoring products and infant nutrition — that can offer relative resilience across economic cycles. Investors should note its exposure to regulatory approvals, reimbursement policies and competition from large medtech and pharmaceutical peers, plus currency and supply-chain risks in international markets. Abbott invests in R&D and product upgrades, which can support long-term growth but also requires ongoing capital. The company has historically returned cash to shareholders, yet past distributions do not guarantee future payments. This summary is for general, educational purposes and is not personalised investment advice; individuals should assess suitability, consult up-to-date sources, and consider seeking regulated financial advice before investing.
Why It's Moving
Analysts Rally Behind ABT with Strong Buy Ratings Eyeing Robust 2026 Growth
- BTIG's Marie Thibault reiterated Strong Buy on April 17, emphasizing ABT's neuromodulation portfolio boosted by fresh FDA approvals for higher-margin growth.
- Goldman Sachs' David Roman maintained Strong Buy on April 9, citing resilient diagnostics recovery and nutrition stability driving consistent operating efficiency.
- FreeStyle Libre CGM sales surged to $2B in Q4 2025 with 15% growth, while the pending $21B Exact Sciences deal promises enhanced cancer diagnostics capabilities.
Analysts Rally Behind ABT with Strong Buy Ratings Eyeing Robust 2026 Growth
- BTIG's Marie Thibault reiterated Strong Buy on April 17, emphasizing ABT's neuromodulation portfolio boosted by fresh FDA approvals for higher-margin growth.
- Goldman Sachs' David Roman maintained Strong Buy on April 9, citing resilient diagnostics recovery and nutrition stability driving consistent operating efficiency.
- FreeStyle Libre CGM sales surged to $2B in Q4 2025 with 15% growth, while the pending $21B Exact Sciences deal promises enhanced cancer diagnostics capabilities.
When is the next earnings date for Abbott (ABT)?
Abbott Laboratories is estimated to announce its Q2 2026 earnings between July 16 and July 20, 2026, based on the company's historical earnings release patterns, as an official date has not yet been announced. The next earnings report will cover the second quarter of 2026 and will include updates on financial performance following the Q1 2026 results released on April 16. Investors should monitor Abbott's investor relations website for confirmation of the specific date as it approaches.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Abbott's stock, indicating strong confidence in its future growth potential.
Financial Health
Abbott is successfully generating strong revenue and profits, indicating solid financial performance.
Dividend
Abbott's average dividend yield of 2.62% provides a modest return for dividend-seeking investors. If you invested $1000 you would be paid $26.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
AVANTOR INC
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
Baskets Featuring ABT
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Stable revenue mix
Recurring sales from diagnostics and devices can support steadier cash flows, though performance will vary and is not guaranteed.
Global market reach
A broad international footprint offers growth opportunities but brings currency, regulatory and supply-chain exposure to watch.
Product innovation focus
Ongoing R&D and device upgrades can drive long-term growth, yet new product development faces regulatory and competitive hurdles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
